Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 7/20 | 0.37 |
| ▸ | MMP3 | P08254 | 7/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.30 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.30 |
| ▸ | TLR4 | O00206 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13614286 | 0.95 | MMP2 (0.36) | MMP2MMP3NPC1CASP3RAB9A | |
| SCHEMBL13614310 | 0.92 | MAPT (0.33) | MMP2MMP3NPC1CASP3RAB9A | |
| SCHEMBL10806975 | 0.89 | NPC1 (0.40) | NPC1CASP3RAB9ASENP8NLRP3 | |
| SCHEMBL10806983 | 0.89 | NPC1 (0.40) | NPC1CASP3RAB9ASENP8NLRP3 | |
| SCHEMBL23618038 | 0.82 | CASP3 (0.36) | NPC1CASP3RAB9ASENP8NLRP3 | |
| SCHEMBL22483694 | 0.81 | CASP3 (0.35) | NPC1CASP3RAB9ASENP8NLRP3 | |
| SCHEMBL10896353 | 0.80 | TLR4 (0.41) | NPC1CASP3RAB9ASENP8NLRP3 | |
| SCHEMBL10896345 | 0.80 | TLR4 (0.41) | NPC1CASP3RAB9ASENP8NLRP3 | |
| SCHEMBL10892869 | 0.79 | ESR2 (0.36) | NPC1CASP3RAB9ASENP8NLRP3 | |
| SCHEMBL10892864 | 0.79 | ESR2 (0.36) | NPC1CASP3RAB9ASENP8NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618690-B2 | Polymerizable liquid crystal compound, liquid crystal composition, optical anisotropic material and optical element | ASAHI GLASS COMPANY, LIMITED (JP) | 2009-11-17 | — | — | US | disclosed |
| US-7618690-B2 | Polymerizable liquid crystal compound, liquid crystal composition, optical anisotropic material and optical element | ASAHI GLASS COMPANY, LIMITED (JP) | 2009-11-17 | — | — | US | disclosed |
| US-20080204650-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION, OPTICAL ANISOTROPIC MATERIAL AND OPTICAL ELEMENT | ASAHI GLASS COMPANY LIMITED (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080204650-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION, OPTICAL ANISOTROPIC MATERIAL AND OPTICAL ELEMENT | ASAHI GLASS COMPANY LIMITED (JP) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080204650-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION, OPTICAL ANISOTROPIC MATERIAL AND OPTICAL ELEMENT | CCNE2, CCNE1, CCNL2 | MMP2 3774/4885MMP3 4040/4885NPC1 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.